Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ROSE12 in Locally Advanced or Metastatic Solid Tumors
NCT05907980Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2023
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of ROSE12 in solid tumor (6 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose and Recommended Dose, Safety and Tolerability (Adverse Events) up to 43 months and 4 more. Started May 2023; status: recruiting.
02
Drugs
ROSE12
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05907980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907980.